Therapeutic compounds and methods of use
AssigneeTrustees of Dartmouth College
InventorsGordon W. Gribble, Tadashi Honda, Michael B. Sporn, Nanjoo Suh
Life of this patent
Estimating the term…
Abstract
Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.
Claims61
A method of treating a disorder selected from cancer, neurodegenerative diseases, and inflammatory diseases, comprising administering to said subject a pharmaceutically effective amount of a composition having the formula:
- wherein either A or B is a double bond such that when A is a double bond, C11 has substituted thereon ═X, which is an organic or inorganic moiety and when B is a double bond, C12 has substituted thereon ═X, which is an organic or inorganic moiety;
- R1 is an organic or inorganic moiety which may be substituted anywhere on the six-membered ring denoted by positions 1 through 10;
- R2 and R3 are hydrogen or organic or inorganic moieties, wherein an R2 group may be substituted anywhere on the structure represented in formula (I);
- and n is a number from 0 to 100, such that said disorder is treated.
A method of inhibiting interferon γ-induced nitric oxide production in cells of a subject, comprising administering to said subject a pharmaceutically effective amount of a composition having the formula:
- wherein either A or B is a double bond such that when A is a double bond, C11 has substituted thereon ═X, which is an organic or inorganic moiety and when B is a double bond, C12 has substituted thereon ═X, which is an organic or inorganic moiety;
- R1 is an organic or inorganic moiety which may be substituted anywhere on the six-membered ring denoted by positions 1 through 10;
- R2 and R3 are hydrogen or organic or inorganic moieties, wherein an R2 group may be substituted anywhere on the structure represented in formula (I);
- and n is a number from 0 to 100, such that said nitric oxide production is inhibited.
A method of decreasing transcription of iNOS or COX-2 genes, comprising administering to a subject a pharmaceutically effective amount of a composition having the formula:
- wherein either A or B is a double bond such that when A is a double bond, C11 has substituted thereon ═X, which is an organic or inorganic moiety and when B is a double bond, C12 has substituted thereon ═X, which is an organic or inorganic moiety;
- R1 is an organic or inorganic moiety which may be substituted anywhere on the six-membered ring denoted by positions 1 through 10;
- R2 and R3 are hydrogen or organic or inorganic moieties, wherein an R2 group may be substituted anywhere on the structure represented in formula (I);
- and n is a number from 0 to 100, such that transcription of said iNOS or COX-2 genes is decreased.
A method of treating a neurodegenerative disease, comprising administering to a subject a pharmaceutically effective amount of a composition having the formula:
- wherein either A or B is a double bond such that when A is a double bond, C11 has substituted thereon ═X, which is an organic or inorganic moiety and when B is a double bond, C12 has substituted thereon ═X, which is an organic or inorganic moiety;
- R1 is an organic or inorganic moiety which may be substituted anywhere on the six-membered ring denoted by positions 1 through 10;
- R2 and R3 are hydrogen or organic or inorganic moieties, wherein an R2 group may be substituted anywhere on the structure represented in formula (I);
- and n is a number from 0 to 100, such that said neurodegenerative disease is treated in said subject.
A method of treating a disorder characterized by overexpression of iNOS or COX-2 genes, comprising administering to a subject a pharmaceutically effective amount of a composition having the formula:
- wherein A or B is a single or double bond and C11 or C12 have substituted thereon ═X, which is an organic or inorganic moiety;
- R1 is an organic or inorganic moiety which may be substituted anywhere on the six-membered ring denoted by positions 1 through 10;
- R2 and R3 are hydrogen or organic or inorganic moieties, wherein an R2 group may be substituted anywhere on the structure represented in formula (I);
- and n is a number from 0 to 100, such that said disorder is treated.
A method for treating a condition in a subject caused by activated macrophages comprising administering to the a compound having the formula:
- wherein either A or B is a double bond such that when A is a double bond, C11 has substituted thereon ═X, which is an organic or inorganic moiety and when B is a double bond, C12 has substituted thereon ═X, which is an organic or inorganic moiety;
- R1 is an organic or inorganic moiety which may be substituted anywhere on the six-membered ring denoted by positions 1 through 10;
- R2 and R3 are hydrogen or organic or inorganic moieties, wherein an R2 group may be substituted anywhere on the structure represented in formula (I);
- and n is a number from 0 to 100;
- and wherein said compound is dispersed in a pharmaceutically effective carrier in an amount effective to decrease macrophage activity, thereby treating the condition.
A method of treating a disorder characterized by overexpression of iNOS or COX-2 genes, comprising administering to a subject a pharmaceutically effective amount of a composition having the formula:
- wherein either A or B is a double bond such that when A is a double bond, C11 has substituted thereon ═X, which is an organic or inorganic moiety and when B is a double bond, C12 has substituted thereon ═X, which is an organic or inorganic moiety;
- R1 is an organic or inorganic moiety which may be substituted anywhere on the six-membered ring denoted by positions 1 through 10;
- R2 and R3 are hydrogen or organic or inorganic moieties, wherein an R2 group may be substituted anywhere on the structure represented in formula (I);
- and n is a number from 0 to 100, such that the disorder is treated.
Dependencies are inferred from the claim text.